Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × elotuzumab × 90 days × Clear all

Phase

Phase 3 4 Phase 2 4 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 8 Specimen Handling 8 Magnetic Resonance Spectroscopy 7 Biopsy 6 Radiotherapy 5 Nivolumab 5 Dexamethasone 4 Bevacizumab 4 tremelimumab 3 encorafenib 3 X-Rays 3 Tirzepatide 3 Radiation 3 Immunotherapy, Adoptive 3 Immunoglobulin G 3 Folfox protocol 3 Disulfides 3 Cyclophosphamide 3 Cisplatin 3 venetoclax 2 tislelizumab 2 olaparib 2 niraparib 2 fludarabine 2 durvalumab 2 binimetinib 2 Watchful Waiting 2 Vaccines 2 Standard of Care 2 Simvastatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡